Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.

ABSTRACT:

Background

Approximately 90% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by the untargetable non-G12C KRAS mutations, and only a small subset of patients are eligible for FDA-approved precision therapies. The practice of precision therapy in pancreatic cancer was limited by the paucity of targetable genetic alterations, especially in the Asian population.

Methods

To explore therapeutic targets in 499 Chinese PDAC patients, a deep sequencing panel (OncoPanscan™, Genetron health) was used to characterize somatic alterations including point mutations, indels, copy number alterations, gene fusions as well as pathogenic germline variants.

Results

We performed genomic profiling in 499 Chinese PDAC patients, which revealed somatic driver mutations in KRAS, TP

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC10242355 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature